Fresh analysis indicates that individuals who stop using popular slimming jabs like Wegovy and Mounjaro can put back on lost weight far faster than those who end conventional diet and exercise regimens.
Findings released in a prominent medical journal demonstrates that while overweight people can lose a large proportion of their total mass while using the jabs, the mass comes back at an average rate of 0.8 kg per month after stopping.
"Individuals buying such medications should be cognizant of the danger of rapid rebound weight gain when the treatment is stopped," warns researcher Dr. Susan Jebb.
Such speed of regain means a reversion to starting mass within about a year and a half.
Analyzing Therapies
The research, which reviewed 37 of trials involving thousands of patients, compared the results of these new drugs with conventional dieting.
Researchers note that people who shed pounds through diet and exercise usually see a less rapid creep back—perhaps 100 grams monthly—once they finish.
Understanding the Rapid Rebound
Doctors propose the way of the jabs is key to understanding the amplified weight return.
The injections copy a body's own chemical called glucagon-like peptide-1, which controls hunger.
"Artificially providing GLP-1 levels far above than normal may cause the body to produce less of its own natural hormone, and could diminish responsiveness to its actions," said Dr. Adam Collins, a dietetics expert.
"Withdrawal of this GLP-1 'fix' leads to hunger is uncontrolled, making excessive eating much more probable."
A Chronic Condition?
The NHS suggest the jabs for individuals with weight-linked health risks, alongside prescribed lifestyle changes.
A number of clinicians say that, due to the significant potential of weight regain, the treatment is often long-term.
This perspective is echoed by drug manufacturers, who note that the results "highlight the long-term character of excess weight," akin to managing conditions like diabetes.
User Accounts
Users who have discontinued the jabs describe a sudden return of cravings.
"It was like a switch flipping and you're instantly ravenous," recalled a patient.
The struggle is compounded if patients have not established sustainable lifestyle or habit changes during therapy.
Widespread Use
Survey data suggest that a significant number of adults in the UK have tried these injections in the past year, with demand continuing to grow.
- Adoption is greater among women compared to males.
- The middle-aged age group shows the greatest level of interest.
- Many access the drugs through private prescriptions rather than public health services.
In conclusion, experts emphasize that while these medications are potent agents for weight loss, they are not a magic cure and lasting health benefits likely depends on integrated behavioural support.
